The Danish vaccine company says the upgrade reflects stronger-than-expected performance in its Travel Health business. Guidance for that segment rises from about DKK 3,000 million to about DKK 3,400 million. According to the company, increased animal rabies activity in the US has led to a significant rise in human exposure, boosting demand for both pre- and post-exposure vaccination.

The expected EBITDA margin rises from about 30% to about 32%. Guidance for the Public Preparedness business is unchanged at about DKK 2,500 million, of which about DKK 2,400 million has been secured in orders so far. Other revenue remains at DKK 200 million.

The company began the year guiding for revenue of DKK 5,000–5,200 million and has raised the outlook in May, August and now October.